453565-67-8

Upstream product

• 106-95-6 allyl bromide 
• 21368-39-8 dimethyl 5-(prop-2-en-1-yloxy)benzene-1,3-dicarboxylate 
• 13036-02-7 Dimethyl 5-hydroxyisophthalate 

Downstream Products

• 932380-60-4 methyl 3-(allyloxy)-5-{[(benzyloxy)amino]carbonyl}benzoate 
• 900799-47-5 5-allyloxy-N-(2,2-dimethoxy-ethyl)-isophthalamic acid methyl ester 
• 522616-57-5 3-allyloxy-5-chlorocarbonyl-benzoic acid methyl ester 
• 453565-68-9 methyl 3-(allyloxy)-(5-aminocarbonyl)benzoate 
• 212208-04-3 (3-Allyloxy-5-{2,2,2-trifluoro-1-[(Z)-hydroxyimino]-ethyl}-phenyl)-carbamic acid tert-butyl ester 
• 212207-96-0 2-<5-nitro-3-(3-trifluoromethyl-1,2-diazirin-3-yl)phenoxy>ethanal 
• 212208-02-1 3-Allyloxy-5-{2,2,2-trifluoro-1-[(Z)-hydroxyimino]-ethyl}-benzoic acid methyl ester 
• 212208-00-9 3-Allyloxy-5-(2,2,2-trifluoro-acetyl)-benzoic acid methyl ester 
• 212207-98-2 3-allyloxy-5-formyl-benzoic acid methyl ester 
• 900800-44-4 methyl 3-allyloxy-5-(hydroxymethyl)benzoate 

Relevant academic research and scientific papers

Macrocyclic Compounds Useful as Bace Inhibitors

The invention relates to novel macrocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

Inhibitors of the FEZ-1 metallo-β-lactamase

Metallo-β-lactamases (MBLs) catalyze the hydrolysis of β-lactams including penicillins, cephalosporins and carbapenems. Starting from benzohydroxamic acid (1) structure-activity studies led to the identification of selective inhibitors of the FEZ-1 MBL, e.g., 2,5-substituted benzophenone hydroxamic acid 17 has a Ki of 6.1 ± 0.7 μM against the FEZ-1 MBL but does not significantly inhibit the IMP-1, BcII, CphA or L1 MBLs.

Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.